Jonathan Van-Tam on COVID’s Next Phase - Summary - DentalSpire
Commentary & Perspectives

Jonathan Van-Tam on COVID’s Next Phase

Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19

Share

Professor Sir Jonathan Van-Tam, former Deputy Chief Medical Officer for England, discusses the evolving landscape of COVID-19 vaccination, specifically the introduction of Sanofi's Nuvaxovid vaccine in the UK’s Spring 2026 program. He highlights that while COVID-19 remains a public health concern akin to seasonal flu, the introduction of diverse vaccine technologies—including protein-based options like Nuvaxovid—could address vaccine hesitancy. He emphasizes lessons learned from the pandemic about the importance of having multiple vaccine platforms and the growing need for adult immunization.

Original Source(s)

Jonathan Van-Tam on COVID’s Next Phase

  • by James Strachan, Julian Upton

  • April 14, 2026

Related Content

Viral, Fungal Infections May Contribute to Nonresolving ARDS

Review links viral and fungal infections to persistent lung injury in nonresolving ARDS

Hidden Parasite Spreads to Washington

Findings in coyotes signal new challenges for diagnostics and surveillance

  • April 16, 2026

  • 2 min
Hidden Leprosy Cases Uncovered

Reused COVID-19 samples reveal missed infections and new diagnostic opportunities

  • April 15, 2026

  • 2 min